E.E. Geduld’s Alaunos Therapeutics TCRT Stock Holding History

E.E. Geduld’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$54K	Hold	67	–	–	0.03%	132
2016 Q3	$56K	Buy	+67	New	+$53.9K	0.06%	143
2016 Q2	–	Sell	-134	Closed	-$149K	–	182
2016 Q1	$149K	Buy	134 +67	+100%	+$68.6K	0.2%	82
2015 Q4	$83K	Buy	+67	New	+$111K	0.05%	124
2015 Q3	–	Sell	-189	Closed	-$341K	–	267
2015 Q2	$341K	Sell	189 -312	-62%	-$484K	0.21%	105
2015 Q1	$809K	Buy	501 +101	+25%	+$150K	0.54%	31
2014 Q4	$304K	Buy	400 +333	+497%	+$177K	0.16%	102
2014 Q3	$26K	Hold	67	–	–	0.02%	210
2014 Q2	$40K	Sell	67 -100	-60%	-$55.7K	0.02%	255
2014 Q1	$115K	Hold	167	–	–	0.06%	217
2013 Q4	$109K	Hold	167	–	–	0.05%	241
2013 Q3	$99K	Buy	+167	New	+$75.3K	0.06%	217

Other funds holding TCRT

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

E.E. Geduld's TCRT Position: Q4 2016 in Review

E.E. Geduld held its Alaunos Therapeutics (TCRT) position steady in Q4 2016 at 67 shares worth $54K. The position accounts for 0.03% of the portfolio, ranked #132.

E.E. Geduld first reported a position in TCRT in Q3 2013 and has held it in 12 quarters since. The position peaked at $809K in Q1 2015. 136 funds tracked by Wall St. Rank hold TCRT as of Q4 2016.

E.E. Geduld held 67 shares of Alaunos Therapeutics worth $54K as of Q4 2016.
E.E. Geduld left its Alaunos Therapeutics share count unchanged in Q4 2016.
Alaunos Therapeutics made up 0.03% of E.E. Geduld's portfolio in Q4 2016, its #132 holding.
E.E. Geduld first reported a position in Alaunos Therapeutics in Q3 2013 and has held it in 12 quarters since.
E.E. Geduld's Alaunos Therapeutics position peaked at $809K in Q1 2015.
136 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2016.

Based on E.E. Geduld's 13F filing for Q4 2016, filed 8 Feb 2017.